metformin and fenofibrate

metformin has been researched along with fenofibrate in 45 studies

Research

Studies (45)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (40.00)	29.6817
2010's	26 (57.78)	24.3611
2020's	1 (2.22)	2.80

Authors

Authors	Studies
Agarwal, SC; Chander, R; Khaliq, T; Narender, T; Papi Reddy, K; Prathipati, P; Puri, A; Raj, K; Shweta, S; Srivastava, AK; Tiwari, P	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Maurya, R; Singh, AB; Srivastava, AK	1
Narender, T; Papi Reddy, K; Puri, A; Singh, AB; Srivastava, AK	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Dwivedi, AK; Nath, C; Pratap, R; Raghubir, R; Satyanarayana, M; Singh, AB; Singh, H; Singh, SK; Srivastava, AK; Srivastava, M; Srivastava, SP; Tiwari, P; Verma, AK	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Tuomilehto, J	1
Alvarez Fidalgo, P; Codoceo, R; Díez, JJ; Iglesias, P	1
Athyros, VG; Elisaf, M; Mikhailidis, DP	1
Bauer, MF; Francesconi, C; Hohenecker, J; Ledl, M; Roden, M; Roots, I	1
Guo, XH; Wang, NH; Wang, W; Wu, HH; Xu, XS	1
Guo, XH; Wang, NH; Wang, W	1
Kastelein, JJ; Nieuwdorp, M; Stroes, ES	1
Abdallah, P; Basset, A; Beylot, M; Bricca, G; Del Carmine, P; Forcheron, F; Metais, C	1
Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A	1
Dieterich, HA; Dole, WP; Howard, D; Maboudian, M; Vaidyanathan, S; Warren, V; Yeh, CM	1
Abdallah, P; Basset, A; Beylot, M; Del Carmine, P; Forcheron, F; Gadot, N	1
Krysiak, R; Okopien, B; Pruski, M	1
Al-Mousawi, AM; Gauglitz, GG; Herndon, DN; Jeschke, MG; Mecott, GA	1
Abdallah, P; Basset, A; Beylot, M; del Carmine, P; Forcheron, F; Haffar, G	1
Basset, A; Beylot, M; Del Carmine, P; Forcheron, F	1
Aslanidis, C; Bauer, S; Buechler, C; Luchner, A; Neumeier, M; Schäffler, A; Schnitzbauer, AA; Wanninger, J; Weigert, J	1
Feng, L; Gao, G; Gao, L; Guan, Q; Liu, Y; Wan, Q; Wang, C; Wang, F; Zhao, J	1
Bundrick, JB; Litin, SC	1
Gdula-Dymek, A; Krysiak, R; Okopien, B	4
Colman, PG; Donoghoe, M; Forder, P; Graham, N; Haapamäki, H; Keech, A; Kritharides, L; Merrifield, A; Simes, J; Sullivan, D; Whiting, M	1
Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN	1
Rehman, HU	1
Cho, YM; Kang, GH; Oh, TJ; Park, KS; Shin, JY	1
Arnett, TR; Butters, OR; Patel, JJ	1
Lee, WL; Loo, SC; Tan, CN; Tan, JW	1
Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M	1
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N	1
Anabtawi, A; Miles, JM; Moriarty, PM	1
Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A	1

Reviews

4 review(s) available for metformin and fenofibrate

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia. Diabetes research and clinical practice, 2003, Volume: 61 Suppl 1 Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
The role of hyperglycemia in burned patients: evidence-based studies. Shock (Augusta, Ga.), 2010, Volume: 33, Issue:1 Topics: Blood Glucose; Burns; Fenofibrate; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin	2010
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. Current cardiology reports, 2017, Volume: 19, Issue:7 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metformin; Pioglitazone; Thiazolidinediones	2017

Trials

10 trial(s) available for metformin and fenofibrate

Article	Year
Inflammatory markers and the metabolic syndrome. Atherosclerosis, 2005, Volume: 183, Issue:1 Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome	2005
Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:6 Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Treatment Outcome	2007
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes care, 2009, Volume: 32, Issue:8 Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibrinogen; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Placebos; Plasminogen Activator Inhibitor 1; Risk Factors	2009
Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:11 Topics: Adolescent; Adult; Aged; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Prediabetic State; Young Adult	2010
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. The American journal of cardiology, 2011, Apr-01, Volume: 107, Issue:7 Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Lymphocytes; Male; Metformin; Middle Aged; Monocytes; Prospective Studies; Simvastatin; Systemic Inflammatory Response Syndrome	2011
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes research and clinical practice, 2011, Volume: 94, Issue:2 Topics: Administration, Oral; Aged; Australia; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome	2011
Combination therapy with metformin and fenofibrate for insulin resistance in obesity. The Journal of international medical research, 2011, Volume: 39, Issue:5 Topics: Adult; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperinsulinism; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Treatment Outcome; Young Adult	2011
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. Pharmacological reports : PR, 2013, Volume: 65, Issue:1 Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intolerance; Hemostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Prediabetic State; Single-Blind Method	2013
Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacological reports : PR, 2013, Volume: 65, Issue:2 Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Intercellular Adhesion Molecule-1; Lipids; Lymphocytes; Male; Metformin; Middle Aged	2013
Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacological reports : PR, 2013, Volume: 65, Issue:5 Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Female; Fenofibrate; Glucose Intolerance; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Lipids; Male; Metformin; Middle Aged; Monocytes; Poland; Time Factors; Treatment Outcome; Young Adult	2013

Other Studies

31 other study(ies) available for metformin and fenofibrate

Article	Year
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos. Bioorganic & medicinal chemistry letters, 2007, Mar-15, Volume: 17, Issue:6 Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Aegle; Animals; Blood Glucose; Cholesterol; Cholesterol, HDL; Cricetinae; Diabetes Mellitus, Experimental; Dietary Fats; Fatty Acids, Nonesterified; Hypoglycemic Agents; Hypolipidemic Agents; Male; Models, Molecular; Phospholipids; Rats; Rats, Sprague-Dawley; Triglycerides	2007
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity. Bioorganic & medicinal chemistry letters, 2008, Dec-15, Volume: 18, Issue:24 Topics: Animals; Chemistry, Pharmaceutical; Diabetes Mellitus, Experimental; Hyperglycemia; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Metformin; Mice; Mice, Inbred C57BL; Plant Extracts; Rats; Rats, Sprague-Dawley; Withania; Withanolides	2008
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemistry, Pharmaceutical; Cricetinae; Diabetes Mellitus, Experimental; Drug Design; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Models, Chemical; Pentacyclic Triterpenes; Rats; Streptozocin; Triglycerides; Triterpenes	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Flavone-based novel antidiabetic and antidyslipidemic agents. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Animals; Biological Availability; Cholesterol; Cricetinae; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Flavones; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Streptozocin; Structure-Activity Relationship; Triglycerides	2012
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations. Endocrine journal, 2004, Volume: 51, Issue:3 Topics: Adiponectin; Aged; Blood Glucose; Cytokines; Diabetes Mellitus, Lipoatrophic; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hormones, Ectopic; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Leptin; Metformin; Resistin; Tumor Necrosis Factor-alpha; Weight Loss	2004
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetologia, 2005, Volume: 48, Issue:10 Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Muscular Diseases; Rosiglitazone; Thiazolidinediones	2005
[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2006, Apr-18, Volume: 38, Issue:2 Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Kidney; Lipid Metabolism; Metformin; Rats; Rats, Inbred OLETF; Sterol Regulatory Element Binding Protein 1	2006
[Change in ghrelin level with the amelioration of glucose and lipid metabolic disorder in OLETF rats]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2006, Dec-18, Volume: 38, Issue:6 Topics: Animals; Blotting, Northern; Diabetes Mellitus, Type 2; Fenofibrate; Gastric Mucosa; Ghrelin; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Random Allocation; Rats; Rats, Inbred OLETF; RNA, Messenger; Stomach	2006
Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:7 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Eating; Fatty Acids, Nonesterified; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; PPAR alpha; Rats; Rats, Zucker; Receptors, Adiponectin; RNA, Messenger; Triglycerides	2008
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. The Journal of pharmacy and pharmacology, 2008, Volume: 60, Issue:9 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides	2008
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Current medical research and opinion, 2008, Volume: 24, Issue:8 Topics: Adolescent; Adult; Amides; Antihypertensive Agents; Area Under Curve; Chromatography, Liquid; Drug Interactions; Female; Fenofibrate; Fumarates; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Renin; Tandem Mass Spectrometry; Thiazolidinediones	2008
Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat. Cardiovascular diabetology, 2009, Mar-24, Volume: 8 Topics: Animals; Blood Glucose; Cardiomyopathies; Diabetes Mellitus, Experimental; Disease Models, Animal; Fenofibrate; Male; Metformin; Rats; Rats, Zucker	2009
Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:7 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Eating; Energy Metabolism; Fatty Acids; Fatty Liver; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; PPAR alpha; Rats; Rats, Zucker; RNA, Messenger; Triglycerides	2009
Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate. Diabetes & metabolism, 2009, Volume: 35, Issue:6 Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Nonesterified; Fenofibrate; Heart; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Membrane Proteins; Metformin; Myocardium; Obesity; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triglycerides	2009
Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals. Archives of medical research, 2010, Volume: 41, Issue:2 Topics: 3T3-L1 Cells; Adipocytes; Aged; Animals; Diabetes Mellitus; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Intra-Abdominal Fat; Male; Metformin; Mice; Middle Aged; Rats; Rats, Zucker; Receptors, Adiponectin	2010
Clinical pearls in general internal medicine. Mayo Clinic proceedings, 2011, Volume: 86, Issue:1 Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Infective Agents, Urinary; Antihypertensive Agents; Calcium Channel Blockers; Creatinine; Diagnosis, Differential; Female; Fenofibrate; Gout; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Internal Medicine; Losartan; Male; Metformin; Nifedipine; Potassium; Sulfonamides; Tamsulosin; Trimethoprim; Ureteral Calculi; Vitamin B 12 Deficiency	2011
The work-up for mixed hyperlipidemia: a case study. The Journal of family practice, 2012, Volume: 61, Issue:3 Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Male; Metformin; Physical Examination; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2012
Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats. Experimental & molecular medicine, 2013, Jul-05, Volume: 45 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exenatide; Feeding Behavior; Fenofibrate; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Tolerance Test; Homeostasis; Immunohistochemistry; Injections, Intraperitoneal; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Peptides; Rats; Receptors, Glucagon; Venoms	2013
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell biochemistry and function, 2014, Volume: 32, Issue:4 Topics: Adipogenesis; Animals; Cell Differentiation; Cells, Cultured; Chromans; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Droplets; Metformin; Mice; Osteoblasts; Osteoclasts; Osteogenesis; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone	2014
Modulating drug release from gastric-floating microcapsules through spray-coating layers. PloS one, 2014, Volume: 9, Issue:12 Topics: Capsules; Coated Materials, Biocompatible; Delayed-Action Preparations; Fenofibrate; Half-Life; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Piroxicam	2014
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. Journal of pediatric endocrinology & metabolism : JPEM, 2015, Volume: 28, Issue:1-2 Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Glucose Intolerance; Humans; Infant; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Metabolome; Metformin; Pituitary Neoplasms; Retrospective Studies	2015
Reducing CV risk in diabetes: An ADA update. The Journal of family practice, 2017, Volume: 66, Issue:5 Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones	2017
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats. PloS one, 2022, Volume: 17, Issue:9 Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Insulin; Liraglutide; Male; Metformin; Obesity; Ramipril; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosuvastatin Calcium; Somatostatin	2022